Literature DB >> 26286071

A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine.

Amaal J Starling1, Bert B Vargas.   

Abstract

Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26286071     DOI: 10.1007/s11916-015-0521-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  40 in total

1.  Low-dose caffeine physical dependence in humans.

Authors:  R R Griffiths; S M Evans; S J Heishman; K L Preston; C A Sannerud; B Wolf; P P Woodson
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.

Authors:  Elza Magalhães; Carla Menezes; Mauricio Cardeal; Ailton Melo
Journal:  Clin Neurol Neurosurg       Date:  2010-04-18       Impact factor: 1.876

4.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

5.  Topiramate in the treatment of chronic migraine.

Authors:  M Silvestrini; M Bartolini; M Coccia; R Baruffaldi; R Taffi; L Provinciali
Journal:  Cephalalgia       Date:  2003-10       Impact factor: 6.292

6.  Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Authors:  Joel R Saper; Alvin E Lake; Deborah T Cantrell; Paul K Winner; Jeffery R White
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

7.  Adherence to oral migraine-preventive medications among patients with chronic migraine.

Authors:  Zsolt Hepp; David W Dodick; Sepideh F Varon; Patrick Gillard; Ryan N Hansen; Emily B Devine
Journal:  Cephalalgia       Date:  2014-08-27       Impact factor: 6.292

8.  Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.

Authors:  Marcelo E Bigal; Daniel Serrano; Michael Reed; Richard B Lipton
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

9.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

10.  Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine.

Authors:  Roger K Cady; Joel Saper; Kent Dexter; Ryan J Cady; Heather R Manley
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

View more
  7 in total

1.  Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders.

Authors:  Raymond C Tait; McKenzie Ferguson; Christopher M Herndon
Journal:  J Pain Manag Med       Date:  2017-01-30

Review 2.  Riboflavin in Neurological Diseases: A Narrative Review.

Authors:  Domenico Plantone; Matteo Pardini; Giuseppe Rinaldi
Journal:  Clin Drug Investig       Date:  2021-04-22       Impact factor: 2.859

3.  Multi-Disciplinary Management of Athletes with Post-Concussion Syndrome: An Evolving Pathophysiological Approach.

Authors:  Michael J Ellis; John Leddy; Barry Willer
Journal:  Front Neurol       Date:  2016-08-24       Impact factor: 4.003

Review 4.  OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience.

Authors:  Chia-Chun Chiang; Amaal J Starling
Journal:  Ther Adv Neurol Disord       Date:  2017-09-20       Impact factor: 6.570

Review 5.  OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Authors:  James E Frampton; Stephen Silberstein
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 6.  Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.

Authors:  Vincent Martin; Karen Hamrick Samaan; Sheena Aurora; Eric M Pearlman; Chunmei Zhou; Xiaoping Li; Robert Pallay
Journal:  Adv Ther       Date:  2020-04-21       Impact factor: 3.845

7.  A Physiological Approach to Assessment and Rehabilitation of Acute Concussion in Collegiate and Professional Athletes.

Authors:  Michael J Ellis; John Leddy; Dean Cordingley; Barry Willer
Journal:  Front Neurol       Date:  2018-12-20       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.